Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.

Published in: Clinical chemistry and laboratory medicine (2024)

The HYDRASHIFT assay demonstrates high precision, specificity, and utility in the accurate monitoring of treatment responses in MM patients receiving daratumumab. This assay represents a significant advancement in overcoming the diagnostic challenges posed by daratumumab interference.

Keyphrases

multiple myeloma
high throughput
high resolution
mass spectrometry
single cell
smoking cessation